Another milestone in the successful oncology collaboration between AstraZeneca PLC and Merck & Co., Inc. has been reached with approval in Europe granted to Koselugo, the firm's therapy for neurofibromatosis type 1 (NF1), a rare debilitating genetic condition.
Two months after receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the European Commission...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?